Compugen reported $2.43M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 700.63K 81.56M Mar/2026
Bio Path USD 259K 60K Mar/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
Immunic USD 3.45M 451K Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
RedHill Biopharma USD 4.48M 1.52M Mar/2024
TherapeuticsMD USD 1.23M 90K Jun/2024